• Oral anti-arrhythmic agents given at high doses (usually 75-100% of the maintenance dose) has been used successfully to treat patients with atrial fibrillation (AF) of recent onset.
• Due to pro-arrhythmic concerns, this "Pill-in-the-Pocket" (PITP) approach to AF has been limited to patients without structural heart disease (SHD) [1] [2] [3] .
• Ranolazine is an anti-anginal agent which exerts its antianginal effect via an electrophysiologic mechanism; inhibition of the late INa+ current and attenuation of Na + and Ca + overload.
• Ranolazine inhibits after-depolarizations and triggered activity (a mechanism of pulmonary vein firing) and extends the refractory period of atrial tissue.
• Ranolazine decreased episodes of AF in the MERLIN Trial and has no known pro-arrhythmic effects [4] .
• We explored the use of ranolazine as a means to convert new or paroxysmal AF in patients with or without SHD with implications for a safer PITP approach to AF management.
• 32 patients with new or paroxysmal atrial fibrillation of 3-48 hours duration.
• 2,000 mg of ranolazine was administered orally, usually as a single dose.
• Clinical and echocardiographic features of each patient were recorded and presence or absence of structural heart disease determined.
• Adverse events, if any, were noted.
• Success was defined as restoration of sinus rhythm within 6 hours of ranolazine administration.
• Ranolazine given as a 2,000 mg dose was well tolerated and produced no hemodynamic or electrophysiologic adverse events.
• Successful conversion with this dose was achieved in 72% of patients with new or recent onset AF within 6 hours of administration.
• This conversion rate was similar to previously reported PITP protocols and higher than placebo conversion rates [1] [2] [3] .
• This success occurred despite the presence of SHD in most patients.
• Further research and controlled studies regarding this novel use of ranolazine are warranted.
Background: Atrial fibrillation (AF) is the most common arrhythmia requiring treatment. High dose oral anti-arrhythmics (mainly class IC or quinidine) at 75% to 100% of the normal daily dose given as a single dose has been used to convert recent-onset AF. This "pill in the pocket" (PITP) approach has allowed some patients to treat themselves on an as needed basis for infrequent recurrences; however, pro-arrhythmic risk has limited the application of this approach to patients without structural heart disease (SHD). Ranolazine is an anti-anginal agent, which inhibits abnormal late Na+ channel currents, decreases sodium-calcium overload, potently inhibits after-depolarizations, which have been implicated in the initiation and propagation of AF, and has reduced pulmonary vein firing. Ranolazine has no known pro-arrhythmic affects. The ability of ranolazine to terminate AF in man has not been described but if useful could be a safer PITP agent with application in the presence or absence of SHD. We have studied oral ranolazine given as a high loading dose to convert new or paroxysmal AF. Method: 2000 mg of ranolazine were administered to 32 patients with new (14 patients) or paroxysmal (18 patients) AF of at least 3, but not greater than 48 hours duration. Twenty-two patients were in the hospital, 5 in the office, and 5 at home at the time ranolazine was administered. Age, sex, echocardiographic data, associated health conditions and SHD were recorded. Successful conversion was defined as restoration of sinus rhythm within 6 hours of ranolazine administration. Results: All but 4 patients had some form of SHD and 22 had left atrial enlargement. Twenty-three of 32 patients converted to sinus rhythm. No pro-arrhythmic effects, hemodynamic instability, adverse rate effects, or perceived intolerance (other than constipation) were noted. The 72% conversion rate is comparable to other reported PITP protocols and much higher than reported placebo conversion rates. Conclusion: High dose oral ranolazine shows utility as a possible safe agent to convert new or paroxysmal AF. Larger placebo-controlled studies with ranolazine as a PITP method in SHD patients seem warranted.
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Results
• 2,000 mg of ranolazine, given as a single oral dose, was very well tolerated.
• No adverse hemodynamic events were noted.
• No adverse pro-arrhythmic or electrophysiologic events were noted.
• All but 4 patients had some form of structural heart disease and 22 patients had left atrial enlargement.
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